Law360 (April 29, 2021, 5:02 PM EDT) -- Celgene has hit Hikma Pharmaceuticals USA Inc. with a lawsuit in New Jersey federal court seeking to block Hikma from marketing generic versions of the Bristol-Myers Squibb unit's cancer drug Revlimid.
In a patent infringement complaint Wednesday, Celgene Corp. challenged an abbreviated new drug application, or ANDA, that Hikma Pharmaceuticals USA Inc. submitted to the U.S. Food and Drug Administration.
The ANDA is asking the government to allow Hikma to "to manufacture, use, import, distribute, offer to sell and/or sell generic versions of Celgene's Revlimid drug products" before various patents covering the brand-name product have expired, the suit said.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!